Targinta selects ADC-antibody TARG9 as drug candidate

The oncology company Targinta AB, a wholly owned subsidiary of Xintela AB (publ), today announces the selection of the drug candidate TARG9, a conjugated antibody, or ADC (antibody-drug conjugate), targeting the cancer marker integrin α10β1. The candidate, being developed against triple-negative breast cancer and glioblastoma, now enters preclinical development. TARG9 consists of an integrin α10-antibody […]

Xintela starts clinical study of XSTEM® in knee osteoarthritis

Xintela starts its first-in-human study (Phase I/IIa) with XSTEM® for the treatment of knee osteoarthritis in Australia. XSTEM, which consists of allogeneic (donated) integrin alpha10beta1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Patients with moderate knee osteoarthritis (grade II-III) will receive a single injection of XSTEM into the knee joint. Three different doses […]

Xintela AB Year-end report January – December 2021

Summary of the year end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Fourth quarter October 1 – December 31, 2021Income amounted to TSEK 0 (0).Loss before tax totalled TSEK 26,643 (loss: 25,335).Loss per share* was SEK 0.30 (loss: 0.34).At December 31, 2021, the equity/assets ratio** was 16% (57). […]

Xintela granted 4.8 million SEK from Vinnova

Lund, Sweden, January 18, 2022 – Xintela has been granted SEK 4.8 million from Vinnova within the call “New and improved biological drugs in healthcare”. The grant will support a clinical phase I/IIa study to evaluate Xintela’s stem cell product XSTEM® for the treatment of patients with difficult-to-heal leg ulcers. The project, which will be […]

Xintela newsletter January 2022

Dear shareholders, I would like to wish you all a Happy New Year, briefly summarize the past year for Xintela and its subsidiary Targinta, and focus on some important upcoming events that we are looking forward to in 2022. It has been a fantastic and eventful year for our companies with, among other things, an […]

Xintela and ScanVet Animal Health A/S sign Letter of Intent

Xintela announces today that the company has signed a Letter of Intent with the Danish animal health company ScanVet Animal Health A/S. The parties intend to enter into an agreement to develop, market and sell EQSTEM®, Xintela’s proprietary equine stem cell product, for the treatment of joint diseases including osteoarthritis. Under the Letter of Intent, […]

Xintela AB Interim report January – September 2021

Xintela AB Interim report January – September 2021 Summary of the interim report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter July 1 – September 30, 2021 Income amounted to TSEK 0 (0). Loss before tax totalled TSEK 10,910 (loss: 8,315). Loss per share* was SEK 0.13 (loss: […]

Update on status and strategy for Xintela and Targinta

Xintela develops stem cell-based treatments with a focus on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers. We are focused on diseases where there is a high medical need and where effective treatments are lacking today. Solid preclinical R&D has laid the foundation for Xintela’s […]

New board of directors appointed in Targinta AB

Xintela AB announces the appointment of a new board of directors in Targinta AB, a wholly-owned subsidiary of Xintela. Jeffrey Abbey, Karin Wingstrand and Maarten de Château have been appointed as new board members. Gregory Batcheller, chairman, and Evy Lundgren-Åkerlund are already members of the board of Targinta. Gunnar Telhammar resigns as board member. The […]